deferoxamine has been researched along with Abnormalities, Autosome in 11 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Measurements of chromosomal aberrations were made in 10 thalassaemia major patients treated long-term with deferiprone (at least 5 years) and compared with an equal number of patients matched for age, sex and iron overload, treated long-term with deferoxamine." | 2.71 | Chromosomal aberration frequencies in patients with thalassaemia major undergoing therapy with deferiprone and deferoxamine in a comparative crossover study. ( Galanello, R; Kirkland, D; Leoni, G; Marshall, R; Minto, S; Spino, M; Tricta, F, 2003) |
| "Phenolphthalein did not produce DNA strand breaks in rat hepatocytes or DNA adducts in Chinese hamster ovary (CHO) cells." | 1.31 | Induction of chromosome aberrations in vitro by phenolphthalein: mechanistic studies. ( Armstrong, MJ; Galloway, SM; Gara, JP; Gealy, R; Greenwood, SK; Hilliard, CA; Laws, GM, 2000) |
| "Clonogenic survival and chromosomal aberrations were measured in parallel in endothelial cells treated with desferrioxamine after increasing doses of gamma radiation." | 1.30 | Desferrioxamine enhances the effects of gamma radiation on clonogenic survival and the formation of chromosomal aberrations in endothelial cells. ( Juckett, MB; Klein, JP; Shadley, JD; Zheng, Y, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (36.36) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, H | 1 |
| Wang, J | 1 |
| Mor, G | 1 |
| Sklar, J | 1 |
| Marshall, R | 1 |
| Tricta, F | 1 |
| Galanello, R | 1 |
| Leoni, G | 1 |
| Kirkland, D | 1 |
| Minto, S | 1 |
| Spino, M | 1 |
| Ambruso, DR | 1 |
| Mahony, BS | 1 |
| Githens, JH | 1 |
| Rhoades, ED | 1 |
| Jensen, PD | 1 |
| Heickendorff, L | 1 |
| Pedersen, B | 1 |
| Bendix-Hansen, K | 1 |
| Jensen, FT | 1 |
| Christensen, T | 1 |
| Boesen, AM | 1 |
| Ellegaard, J | 1 |
| Juckett, MB | 1 |
| Shadley, JD | 1 |
| Zheng, Y | 1 |
| Klein, JP | 1 |
| Armstrong, MJ | 1 |
| Gara, JP | 1 |
| Gealy, R | 1 |
| Greenwood, SK | 1 |
| Hilliard, CA | 1 |
| Laws, GM | 1 |
| Galloway, SM | 1 |
| Gille, JJ | 1 |
| van Berkel, CG | 1 |
| Joenje, H | 1 |
| Poot, M | 1 |
| Hoehn, H | 1 |
| Porfirio, B | 1 |
| Ambroso, G | 1 |
| Giannella, G | 1 |
| Isacchi, G | 1 |
| Dallapiccola, B | 1 |
| Saddi, R | 1 |
| Feingold, J | 1 |
| Vig, BK | 1 |
| Eyring, EJ | 1 |
1 trial available for deferoxamine and Abnormalities, Autosome
| Article | Year |
|---|---|
Chromosomal aberration frequencies in patients with thalassaemia major undergoing therapy with deferiprone and deferoxamine in a comparative crossover study.
Topics: Adolescent; Adult; beta-Thalassemia; Cell Cycle; Chelation Therapy; Chromosome Aberrations; Cross-Ov | 2003 |
10 other studies available for deferoxamine and Abnormalities, Autosome
| Article | Year |
|---|---|
A neoplastic gene fusion mimics trans-splicing of RNAs in normal human cells.
Topics: Cell Hypoxia; Cell Line; Cell Line, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 17; Chro | 2008 |
Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome.
Topics: Administration, Oral; Anemia, Aplastic; Ascorbic Acid; Blood Transfusion; Child; Chromosome Aberrati | 1982 |
The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload.
Topics: Adolescent; Aged; Bone Marrow Diseases; Chromosome Aberrations; Deferoxamine; Erythropoietin; Female | 1996 |
Desferrioxamine enhances the effects of gamma radiation on clonogenic survival and the formation of chromosomal aberrations in endothelial cells.
Topics: Apoptosis; Cell Cycle; Cell Survival; Chromosome Aberrations; Deferoxamine; DNA Damage; Dose-Respons | 1998 |
Induction of chromosome aberrations in vitro by phenolphthalein: mechanistic studies.
Topics: Animals; Antioxidants; Cathartics; Cell Line; Chelating Agents; CHO Cells; Chromosome Aberrations; C | 2000 |
Effect of iron chelators on the cytotoxic and genotoxic action of hyperoxia in Chinese hamster ovary cells.
Topics: Animals; Cell Survival; CHO Cells; Chromosome Aberrations; Cricetinae; Deferoxamine; Hydrogen Peroxi | 1992 |
Partial correction of chromosome instability in Fanconi anemia by desferrioxamine.
Topics: Anemia, Aplastic; Chromosome Aberrations; Deferoxamine; Fanconi Anemia; Humans; Lymphocytes | 1990 |
Partial correction of chromosome instability in Fanconi anemia by desferrioxamine.
Topics: Anemia, Aplastic; Cells, Cultured; Chromosome Aberrations; Chromosomes, Human; Deferoxamine; Epoxy C | 1989 |
Idiopathic haemochromatosis: an autosomal recessive disease.
Topics: Adolescent; Adult; Aged; Child; Chromosome Aberrations; Chromosome Disorders; Deferoxamine; Female; | 1974 |
Absence of chromosome aberrations in cultured human leukocytes treated by two metal chelators--deferoxamine and penicillamine.
Topics: Chromosome Aberrations; Deferoxamine; DNA; Humans; Leukocytes; Mitosis; Penicillamine | 1971 |